EmerRx
EmerRx Biopharma is a clinical-stage pharmaceutical company developing a proprietary intranasal CNS drug delivery platform optimized for rapid systemic absorption and emergency-use applications. Our platform addresses the core formulation and device challenges limiting first-generation intranasal therapeutics – including Tmax, bioavailability, and dose reliability. Lead program EMRX-101, a next-generation intranasal naloxone product, is advancing under an FDA-agreed 505(b)(2) pathway with clinical pharmacokinetic data demonstrating superior absorption profile versus current standards of care.
